About ElectroCore
ElectroCore is a company based in Basking Ridge (United States) founded in 2005 by JP Errico. ElectroCore has raised $161.39 million across 14 funding rounds from investors including Core Ventures Group, Merck Global Health Innovation Fund and American Investment Holdings. The company has 73 employees as of December 31, 2024. ElectroCore has completed 1 acquisition, including NeuroMetrix. ElectroCore offers products and services including gammaCore and gammaCore Sapphire. ElectroCore operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Basking Ridge, United States
- Employees 73 as on 31 Dec, 2024
- Founders JP Errico
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Electrocore, Inc.
-
Annual Revenue
$25.18 M (USD)57.09as on Dec 31, 2024
-
Net Profit
-$11.89 M (USD)36.89as on Dec 31, 2024
-
EBITDA
-$10.9 M (USD)37.85as on Dec 31, 2024
-
Total Equity Funding
$161.39 M (USD)
in 14 rounds
-
Latest Funding Round
$1.86 M (USD), Post-IPO
Oct 02, 2025
-
Investors
Core Ventures Group
& 4 more
-
Employee Count
73
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ElectroCore
ElectroCore is a publicly listed company on the NASDAQ with ticker symbol ECOR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ElectroCore
ElectroCore offers a comprehensive portfolio of products and services, including gammaCore and gammaCore Sapphire.
Non-invasive stimulator for treating neurological disorders.
Advanced vagus nerve stimulator for specific health applications.
People of ElectroCore
Unlock access to complete
Unlock access to complete
Funding Insights of ElectroCore
ElectroCore has successfully raised a total of $161.39M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.86 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ElectroCore
ElectroCore has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Core Ventures Group, Merck Global Health Innovation Fund and American Investment Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused VC firm investing in seed stage startups in the US
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital is focused on the life science sector.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for ElectroCore
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ElectroCore
ElectroCore has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NeuroMetrix.
Investment portfolio details for ElectroCore
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Wearable technology for pain, nerve disease and sleep disorders
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for ElectroCore
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ElectroCore
Detailed financials for ElectroCore
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Electrocore Comparisons
Peer comparison for ElectroCore
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ElectroCore
ElectroCore operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of ElectroCore
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Electrocore
Complete news archive for ElectroCore
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ElectroCore
ElectroCore was founded in 2005 and raised its 1st funding round 7 years after it was founded.
ElectroCore is headquartered in Basking Ridge, United States. It is registered at Basking Ridge, New Jersey, United States.
Dan Goldberger is the current CEO of ElectroCore.
ElectroCore is a funded company, having raised a total of $161.39M across 14 funding rounds to date.
As of Dec 31, 2024, the latest employee count at ElectroCore is 73.
Annual revenue of ElectroCore is $25.18M as on Dec 31, 2024.
ElectroCore was founded in 2005 and is headquartered in Basking Ridge, United States. Non-invasive vagus nerve stimulation devices, including the portable gammaCore, are developed by the company for medical applications. These devices deliver mild electrical signals to address migraines, cluster headaches, epilepsy, gastric motility disorders, depression, and anxiety. Operations focus on neuromodulation technology within the medical device sector.
ElectroCore's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.
ElectroCore offers gammaCore and gammaCore Sapphire.
Yes, ElectroCore is publicly traded on NASDAQ under the ticker symbol ECOR.
ElectroCore has made 1 acquisition, including NeuroMetrix.
ElectroCore has 5 investors. Key investors include Core Ventures Group, Merck Global Health Innovation Fund, American Investment Holdings, Knoll Capital Management, and Easton Capital Investment Group.
The ticker symbol of ElectroCore is ECOR on NASDAQ.